etoposide has been researched along with Mesothelioma in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (20.00) | 18.7374 |
| 1990's | 9 (30.00) | 18.2507 |
| 2000's | 10 (33.33) | 29.6817 |
| 2010's | 5 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alhebshi, H; Bakker, E; Demonacos, C; Guazzelli, A; Hussain, M; Krstic-Demonacos, M; Meysami, P; Mutti, L; Schwartz, JM; Tian, K | 1 |
| Arslan, D; Bozcuk, H; Coskun, HS; Goksu, SS; Gunduz, S; Mutlu, H; Ozdogan, M; Savas, B; Tatli, AM; Uysal, M | 1 |
| Adiguzel, R; Andreana, PR; Arslan, Z; Ates, M; Bemis, T; Bercovitch, LG; Bögli, S; Boucherez, J; Boudouf, S; Briat, JF; Brown, BM; Busemann, A; Buters, J; Byers, JS; Cairo, MS; Carrier, F; Chalmers, JJ; Chang, E; Chen, J; Chen, Y; Christenson, MK; Cielecka-Piontek, J; Cole, PA; Cooper, BS; Davis, PH; De Silva, RA; Decato, S; DeFries, RS; Demir, V; Denic, A; Deserno, M; Dickey, AM; Diss, E; Eberlein, B; Eyerich, S; Faluvegi, G; Farlow, MR; Fletcher, JW; Francetic, T; Furlan, L; Garbacki, P; Gartung, A; Garvin, JH; Gates, L; Gaymard, F; Ghetti, B; Gibson, MP; Griffin, RG; Hamed, M; Hammad, LA; Hammond, GB; Han, J; Hann, R; Hao, N; Harrison, LA; Heidecke, CD; Hutchins, GD; Inlow, M; Irmer, H; Jani, P; Jara-Cavieres, A; Jawadi, H; Jiang, Q; Jiang, Y; Kameda, T; Keeler, EG; Kim, H; Kim, R; Kim, S; Kinney, PL; Krause, A; Kumar, V; Kwok, Y; Lam, T; Lanni, F; Le May, M; Lee, A; Lee, JF; Lee, MJ; Leontyev, IV; Li, Q; Li, X; Liu, J; Liu, NK; Lominadze, D; Lösche, M; Lu, QB; Lu, Y; Lu, Z; Mach, H; Madsen, E; Marletta, M; Marlier, ME; McDonald, BC; McKay, IS; Mckenzie, CL; Mecozzi, S; Menges, P; Meyers, D; Michaelis, VK; Montooth, KL; Moore, LR; Morgan, JK; Morris, E; Movahed, M; Nalabothula, N; Narayanan, S; Nguyen, D; Nho, K; Oken, B; Ong, TC; Osborne, LS; Paczkowska, M; Park, EK; Pennino, D; Peters, S; Potluri, LP; Qin, C; Radhakrishnan, K; Randerson, JT; Rantanen, J; Reyt, G; Ring, J; Risacher, SL; Rodriguez, M; Saykin, AJ; Schmidt-Weber, CB; Sengelaub, DR; Shatters, RG; Shen, L; Shen, V; Shindell, DT; Stuchebrukhov, AA; Swaminathan, S; Takahashi, K; Talaczyńska, A; Tallman, EF; Tan, C; Terry, SF; Trabbic, KR; Trease, AJ; Tretter, C; Uitto, J; Váradi, A; von Bernstorff, W; Voulgarakis, A; Wagenhofer, M; Wahbeh, H; Wang, EN; Wang, X; Wells, RJ; West, JD; Williams, PS; Wolff, JE; Wootla, B; Xu, B; Xu, XM; Yoder, KK; Zalewski, P; Zan, GH; Zborowski, M; Zhang, HH; Zhang, W; Zhao, J; Zoecklein, L | 1 |
| Betta, PG; Catalano, A; Lazzarini, R; Moretti, S; Orecchia, S; Procopio, A | 1 |
| Hashimoto, M; Hida, T; Iwakami, S; Minakata, K; Nara, T; Ohashi, R; Saya, H; Sekido, Y; Tajima, K; Takahashi, F; Takahashi, K; Yae, T | 1 |
| Dang, NH; Ghani, FI; Iwata, S; Morimoto, C; Naito, M; Yamazaki, H | 1 |
| Bakhshandeh, A; Bruns, I; Dalhoff, K; Demedts, A; Eberhardt, K; Ehlers, EM; Gatzemeier, U; Gruber, Y; Hegewisch-Becker, S; Kaukel, E; Kohlmann, T; Koschel, G; Peters, SO; Robins, HI; Traynor, A; Wiedemann, GJ; Zumschlinge, R | 1 |
| Broaddus, VC; Liu, W; Vivo, C | 1 |
| Bakhshandeh, A; Bruns, I; Kohlmann, T; Wiedemann, GJ | 1 |
| Abayasiriwardana, KS; Broaddus, VC; Hodnett, M; Howard, M; Pespeni, MH; Pittet, JF; Roux, J | 1 |
| Ferraldeschi, R; Lorigan, P; Thatcher, N | 1 |
| Abayasiriwardana, KS; Barbone, D; Broaddus, VC; Dansen, TB; Evan, GI; Hunt, AE; Kim, KU; Lee, KK; Vivo, C | 1 |
| Eagan, RT; Jett, JR | 1 |
| Maasilta, P; Mäntylä, M; Mattson, K; Salo, J; Tammilehto, L | 1 |
| Bagchi, P; Catalano, R; Comis, RL; Hogan, M; LaCreta, FP; Langer, CJ; Nash, S; O'Dwyer, PJ; Rosenblum, N | 1 |
| de Boer-Dennert, M; Goey, SH; Planting, AS; Schellens, JH; Stoter, G; van den Bent, MJ; van der Burg, ME; Verweij, J | 1 |
| Ardizzoni, A; Baas, P; Giaccone, G; Kirkpatrick, A; Mattson, K; Planting, AS; Postmus, PE; Roozendaal, KJ; Sahmoud, T; Schrijver, M; Splinter, TA; Sutedja, T; Tammilehto, L; Van Glabbeke, M; van Pawel, J; van Pottelsberghe, C; van Zandwijk, N | 1 |
| Amano, T; Hatori, S; Imada, T; Ito, H; Kondo, J; Maehara, T; Rino, Y; Shiozawa, M; Suzuki, Y; Takahashi, M | 1 |
| Astoul, P; Boutin, C; Kasseyet, S | 1 |
| Bakhshandeh, A; Bruns, I; Eberhardt, K; Wiedemann, GJ | 1 |
| Anderson, H; Ashcroft, L; Jayson, GC; Ranson, M; Thatcher, N; White, SC | 1 |
| Bando, T; Hasegawa, S; Hirata, T; Inui, K; Omasa, M; Shoji, T; Wada, H | 1 |
| Bernareggi, A; Castoldi, D; Cimino, G; Colombi, L; Fracasso, ME; Leone, R; Monzani, V; Soresi, E; Tedeschi, M; Usari, T | 1 |
| Smith, IE | 1 |
| Berendsen, HH; Postmus, PE; Smit, EF | 1 |
| Devenport, K; Harvey, VJ; Joel, SP; Osborne, RJ; Slevin, ML; Whomsley, R; Wrigley, PF | 1 |
| Harvey, VJ; Joel, SP; Johnston, A; Slevin, ML; Smythe, MM; Wrigley, PF | 1 |
| Harvey, VJ; Joel, SP; Johnston, A; Slevin, ML; Wrigley, PF | 1 |
| Klastersky, J; Sculier, JP; Tueni, E | 1 |
| Eisenhauer, EA; Evans, WK; Kocha, W; Murray, N; Wierzbicki, R; Wilson, K | 1 |
2 review(s) available for etoposide and Mesothelioma
| Article | Year |
|---|---|
Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Etoposide; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Pemetrexed; Randomized Controlled Trials as Topic | 2007 |
[Chemotherapy in combination with whole-body hyperthermia in advanced malignant pleural mesothelioma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; Humans; Hyperthermia, Induced; Ifosfamide; Male; Mesothelioma; Middle Aged; Palliative Care; Pleural Effusion, Malignant; Pleural Neoplasms; Recurrence | 2000 |
11 trial(s) available for etoposide and Mesothelioma
| Article | Year |
|---|---|
Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Hyperthermia, Induced; Ifosfamide; Infusions, Intravenous; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Sepsis; Treatment Outcome | 2003 |
[Evaluation of the therapeutic benefit of 41.8 degrees C whole body hyperthermia plus ifosfamide, carboplatin and etoposide (ICE) for patients with malignant pleural mesothelioma using the Modified Brunner-Score (MBS)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Hyperthermia, Induced; Ifosfamide; Mesothelioma; Pleural Neoplasms; Survival; Survivors | 2004 |
Chemotherapy for malignant mesothelioma; CAMEO.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Male; Mesothelioma; Methotrexate; Middle Aged; Pleural Neoplasms; Prognosis; Radiotherapy Dosage; Vincristine | 1982 |
Oral etoposide in the treatment of malignant mesothelioma. A phase II study.
Topics: Administration, Oral; Adult; Aged; Etoposide; Female; Humans; Male; Mesothelioma; Middle Aged; Peritoneal Neoplasms; Pleural Neoplasms; Remission Induction | 1994 |
Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Treatment Outcome | 1995 |
Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Survival Rate | 1997 |
Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asbestos; Cisplatin; Combined Modality Therapy; Etoposide; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Immunotherapy; Leucovorin; Male; Mesothelioma; Middle Aged; Mitomycin; Pleural Neoplasms; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Analysis; Treatment Outcome | 1999 |
[Chemotherapy in combination with whole-body hyperthermia in advanced malignant pleural mesothelioma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; Humans; Hyperthermia, Induced; Ifosfamide; Male; Mesothelioma; Middle Aged; Palliative Care; Pleural Effusion, Malignant; Pleural Neoplasms; Recurrence | 2000 |
Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Confidence Intervals; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2000 |
Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Interactions; Drug Therapy, Combination; Etoposide; Glutathione; Half-Life; Humans; Lung Neoplasms; Mesothelioma; Platinum; Pleural Neoplasms; Time Factors | 1992 |
Carboplatin in small cell lung cancer: the Royal Marsden Hospital experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Combined Modality Therapy; Cranial Irradiation; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Mesothelioma; Middle Aged; Palliative Care; Pleural Neoplasms; Remission Induction; Survival Rate | 1992 |
18 other study(ies) available for etoposide and Mesothelioma
| Article | Year |
|---|---|
p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.
Topics: Cell Line, Tumor; Cell Survival; Deoxycytidine; Etoposide; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Models, Biological; Neoplasm Staging; Pleural Neoplasms; Proportional Hazards Models; Transcriptome; Tumor Suppressor Protein p53; Wound Healing | 2018 |
Oral cyclophosphamide and etoposide in treatment of malignant pleural mesothelioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pleural Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2014 |
Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Arachidonic Acids; Asbestos; Asbestosis; Attitude of Health Personnel; Carboplatin; Child; Child, Preschool; Curriculum; Databases, Factual; Education, Medical; Enzyme Inhibitors; Etoposide; Europe; Female; General Surgery; Germany; Hospitals, University; Humans; Ifosfamide; Lung Neoplasms; Male; Medical History Taking; Mesothelioma; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Neurons; Muscular Atrophy; Neoplasms; Neuroprotective Agents; Phospholipase A2 Inhibitors; Phospholipases A2, Cytosolic; Physical Examination; Quality Improvement; Spinal Cord Injuries; Topotecan; Universities; World Health Organization; Young Adult | 2014 |
Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Immunoblotting; In Situ Nick-End Labeling; Irinotecan; Male; Mesothelioma; Mice; Mice, Nude; RNA Interference; Transfection; Xenograft Model Antitumor Assays | 2008 |
Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells.
Topics: Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Hyaluronic Acid; Mesothelioma; Osteopontin; Pleural Neoplasms; RNA, Small Interfering; Signal Transduction | 2010 |
Characterization of cancer stem cell properties of CD24 and CD26-positive human malignant mesothelioma cells.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; CD24 Antigen; Cell Division; Cell Line, Tumor; Daunorubicin; Dipeptidyl Peptidase 4; Drug Resistance, Neoplasm; ErbB Receptors; Etoposide; Gene Expression; Gene Knockdown Techniques; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Proteins; Mesothelioma; Neoplasm Invasiveness; Neoplastic Stem Cells; RNA Interference; RNA, Small Interfering | 2012 |
c-Jun N-terminal kinase contributes to apoptotic synergy induced by tumor necrosis factor-related apoptosis-inducing ligand plus DNA damage in chemoresistant, p53 inactive mesothelioma cells.
Topics: Anthracenes; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Caspase 9; Caspases; Cell Survival; DNA Damage; Dose-Response Relationship, Radiation; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Etoposide; Genes, Dominant; Genes, p53; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Membrane Glycoproteins; Mesothelioma; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Recombinant Proteins; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Transfection; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53; Ultraviolet Rays | 2003 |
Sensitization of mesothelioma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by heat stress via the inhibition of the 3-phosphoinositide-dependent kinase 1/Akt pathway.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Caspase 8; Cell Line, Tumor; Etoposide; Hot Temperature; HSP90 Heat-Shock Proteins; Humans; Mesothelioma; Mitochondria; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand | 2007 |
Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim.
Topics: Anisomycin; Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Combined Modality Therapy; Cycloheximide; Drug Synergism; Electrophoresis, Gel, Two-Dimensional; Etoposide; Humans; Immunoblotting; JNK Mitogen-Activated Protein Kinases; Ligands; Membrane Proteins; Mesothelioma; Phosphorylation; Protein Synthesis Inhibitors; Proto-Oncogene Proteins; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured | 2007 |
Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Infusions, Parenteral; Male; Mesothelioma; Middle Aged; Peritoneal Neoplasms; Survival Analysis; Treatment Outcome | 1993 |
A case of malignant peritoneal mesothelioma showed complete remission with chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Caffeine; Cisplatin; Combined Modality Therapy; Drug Combinations; Etoposide; Female; Humans; Mesothelioma; Neoplasms, Unknown Primary; Peritoneal Neoplasms; Remission Induction; Tegafur; Uracil | 1998 |
A case of repetitive intrapleural cancer chemotherapy using INFUSE-A-PORT for malignant mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Chemotherapy, Cancer, Regional Perfusion; Disease Progression; Drug Administration Schedule; Etoposide; Fluorouracil; Humans; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Radiography; Retreatment | 2001 |
Etoposide and mesothelioma.
Topics: Etoposide; Humans; Lung Neoplasms; Mesothelioma; Middle Aged; Remission Induction | 1990 |
The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation.
Topics: Administration, Oral; Biological Availability; Dose-Response Relationship, Drug; Drug Evaluation; Etoposide; Humans; Mesothelioma; Regression Analysis; Time Factors | 1989 |
Variable bioavailability following repeated oral doses of etoposide.
Topics: Adult; Biological Availability; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Humans; Kinetics; Lung Neoplasms; Mesothelioma; Podophyllotoxin; Time Factors | 1985 |
The effect of dose on the bioavailability of oral etoposide.
Topics: Administration, Oral; Adult; Biological Availability; Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Etoposide; Half-Life; Humans; Kinetics; Mesothelioma; Podophyllotoxin; Random Allocation | 1986 |
Phase I study of a carboplatin-etoposide combination in advanced thoracic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Neutropenia; Organoplatinum Compounds; Pancytopenia; Thrombocytopenia | 1988 |
A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. An NCI Canada Clinical Trials Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Male; Mesothelioma; Peritoneal Neoplasms; Pleural Neoplasms | 1988 |